Congresses: Noventure participates at the third edition of FNM

Gelsectan®, Noventure´s new medical device intended for IBS-D, was presented at Noventure´s stand during the 3rd Meeting of the Federation of Neurogastroenterology and Motility, from 29 August to 1 September 2018 in Amsterdam, The Netherlands.

An observational study showing significant symptoms´ improvement in patients with IBS-D treated with Gelsectan® in Spain was presented in the poster session.

Moreover, Noventure hosted a meeting of experts with top European thought leaders in the field of IBS. The faculty agreed on the promising potential of Gelsectan® in the management of IBS-D patients.

Gelsectan® is a class IIa medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments. (CE 0476, Noventure SL).